THANK YOU FOR YOUR TRUST THAT MADE US

The World's No.1
Progestogen®

IF IT'S ORALLY EFFECTIVE, IT'S
duphaston®
Dydrogesterone Tablets IP 10mg

For the use of a Registered Medical Practitioner or a Hospital or a Laboratory only.
Dear Colleagues,

It is a matter of pride and honor for me to present to you this ‘Times of Gynaecology – Decision Tree’. It started as a thought in my mind, to put together a concise, clear and systematic algorithm on important subjects in obstetrics and gynecology. This has germinated and bloomed into a wonderful publication on eleven different topics being presented to you in a simple systematic format.

75 expert gynecologists from across the length and breadth of India got together for two days and brainstormed in groups and together - to bring out this decision tree. Two days of intense debate, discussions, disagreements and consensus, at the end of which these algorithms were put together. They were further modified and then are being brought to you. These of course are only opinions of our experts and not recommendations or guidelines and are only meant to give you all a systematic flow chart to follow, using your own expertise to make final judgements.

I would like to thank Abbott and Science Integra for felicitating these discussions and helping integrate the entire decision tree.

I hope you enjoy reading this decision tree, as much as we enjoyed putting it together.

“The key to pursuing excellence is to embrace an organic, long-term learning process, and not to live in a shell of static, safe mediocrity. Usually, growth comes at the expense of previous comfort or safety.” — Josh Waitzkin

Best wishes!

Dr. Rishma Dhillon Pai

President 2017 - Federation of Obstetrics & Gynaecological Societies of India (FOGSI)
President (Elect- 2018) - Indian Society for Assisted Reproduction (ISAR)
Hon. Gen. Secretary - Indian Association of Gynaecological Endoscopists (IAGE)
Hon. Gen. Secretary- Mumbai Obstetrics and Gynaecological Society
Board Member - World Endometriosis Society (WES)
Preface

Intrauterine insemination (IUI) enhances the probability of pregnancy in subfertile couples. The success of IUI depends on various factors including quality of the luteal phase; and deficiency in this phase is associated with insufficient production of progesterone that is essential for embryo implantation and maintenance of early pregnancy. The clinical conditions that manifest as luteal phase deficiency (LPD) status are stress, polycystic ovary syndrome (PCOS), aging, ovulation stimulation, ovulation induction with or without gonadotropin releasing hormone (GnRH) agonists, and assistant reproductive technologies (ART).

The medication to support luteal phase include progesterones, estrogens, and human chorionic gonadotrophin (hCG). There is an ongoing debate on optimal luteal phase support with many physicians favoring the use of hCG, despite the risk of ovarian hyper-stimulation syndrome (OHSS).

The aim of the FOGSI team is to uncover a protocol which is simple, effective, and acceptable to the patients.
LUTEAL PHASE SUPPORT IN INTRAUTERINE INSEMINATION

Start – on the day of oocyte retrieval

Duration
- IUI – positive pregnancy test to 10–12 weeks of gestation
- IVF – 10–12 weeks of gestation

MODES

Progesterone
(All routes similarly effective, most preferred is oral)
Oral – dydrogesterone 10 mg TDS
Vaginal – MVP 200 mg TDS, Vaginal gel 90 mg OD
LUTEAL PHASE SUPPORT IN INTRAUTERINE INSEMINATION

**MODES**

- **IVF** (LPS needed in all ART cycles)

**Progesterone** (All routes similarly effective)
- Oral – dydrogesterone 10 mg TDS
- Vaginal – MVP 200 mg TDS, vaginal gel 90 mg OD
- IM 50 mg OD
- SC 25 mg OD

**Estrogen (17-β estradiol or estradiol valerate)** + progesterone
- No beneficial effect except in FET
- GnRH agonist trigger
- ‘17-β estradiol has minimal liver load as compared to estradiol valerate

**GnRH agonist–progesterone**
- Triptorelin 0.1 mg SC 6th day after OPU (Definite beneficial effect)

**HCG**
- **HCG along**
  - Not recommended
- **HCG + progesterone**
  - No beneficial effect
  - Beneficial in cycles with GnRH agonist triggers

**ART**: assisted reproductive technology; **CC**: clomiphene citrate; **GnRH**: gonadotropin-releasing hormone; **HCG**: human chronic gonadotropin; **FET**: frozen embryo transfer; **IM**: intramuscular; **IUI**: intrauterine insemination; **IVF**: in-vitro fertilization; **LPS**: luteal phase support; **MVP**: micronized vaginal progesterone; **OD**: once daily; **OPU**: ovum pick-up; **SC**: subcutaneous; **TDS**: trice daily dosing; **IUI**: intrauterine insemination; **IVF**: in-vitro fertilization.

Preface

Infertility is the inability to achieve pregnancy after 12 months of regular, unprotected intercourse. Infertility is estimated to affect one in seven to one in eight couples of reproductive age, with male infertility being responsible for 20% of the cases.

Since, around 85% of couples conceive spontaneously within 12 months of regular intercourse, identifying those who would benefit from infertility evaluation is important. Older women (>35 years) or couples with known risk factors for infertility may require evaluation at 6 months. Moreover, anxiety over infertility may increase stress and decrease libido, further complicating the problem; hence, formal counseling is encouraged for couples experiencing infertility. However, physicians need to be familiar with the workup and prognosis for the infertile couples.

The flowchart guides through the process of approach to an infertile couple, the necessary diagnosis and management strategies are provided as a practical guide for infertility treatment.
FEMALE FACTOR INFERTILITY

Infertility is defined as the inability to conceive despite regular sexual intercourse without using contraception for one year*.

**Preliminary Assessment**
- Age of both partners
- Duration of infertility: duration of infertility and contraceptive use
- Lifestyle: timing of sexual intercourse, alcohol, smoking, drugs, occupation, and stress
- Menstrual/medical/surgical/sexual history and physical examination of both partners
- Obesity/low body weight

**Preliminary Health**
- Folate
- Rubella: if negative, vaccinate the female and wait for 1 month (RCOG)
- Thyroid
- Prolactin
- Thalassemia test of either one of the partner.
- AMH and AFC are recommended and HIV, HBsAg, and Anti-HCV are compulsory for all
Tests for ovulation
- Check for regular menstruation
- Check serum progesterone 7 days prior to expected menstruation
- Serum FSH/LH Day 2–5 of cycle
- Ultrasound monitoring

If abnormal

WHO Group I
Low FSH & E2
- Lifestyle changes
- Weight reduction (BMI <29)/ and MI & DCI (optional)
- CC or Letrozole (3–6 cycles)
- If no ovulation after 3 cycles
  - Offer metformin + CC/Letrozole with/without IUI
  - Gonadotropins /ovarian drilling
- USG monitoring
- Offer Bariatric surgery, if BMI >35

WHO Group II (PCOS), normal FSH, Normal/high LH & E2
- Offer genetic testing (KT)
- Consider donor oocyte

WHO Group III (Ovarian Failure) High FSH, Low E2
- Gonadotropins /ovarian drilling
- USG monitoring
- Offer Bariatric surgery, if BMI >35

If normal

• Test for ovarian reserve
  • Serum AMH/AFC on day 2 USG

If normal

AMH: anti-Mullerian hormone; AFC: antral follicular count; BMI: body mass index; CC: clomiphene citrate; E2: estradiol; FSH: follicle-stimulating hormone; LH: luteinizing hormone; MI & DCI: Myo-inositol & D-chiro-inositol; PCOS: polycystic ovary syndrome; HBsAg: hepatitis B surface antigen; HCV: hepatitis C virus; HIV: human immunodeficiency virus; ICSI: intracytoplasmic sperm injection; RCOG: Royal College of Obstetricians and Gynaecologists; USG: ultrasonography; WHO: World Health Organization.
InFertility

Tests for Tubal Patency after Semen Analysis & Ovulation Assessment

- HSG/HyCoSy
- Hystero/laparoscopy – suspected tubal pathology/ if no conception after 3-4 cycles COS with/without IUI

Normal

Timed intercourse
IUI – 3-4 cycles

Abnormal

If corrected

Corrective tubal surgery

Not corrected

IVF/ICSI

Uterine Factors

Abnormal/damaged/ absent uterus

Surgical correction of pathology

Corrected uterine cavity & one tube patent

TIC
IUI

Rule out genital tuberculosis

Not corrected

IVF Surrogacy
Infertility is defined as the inability to conceive despite regular sexual intercourse without using contraception for one year*.

**Preliminary Assessment**
- Age of both partners
- Duration of infertility: duration of infertility and contraceptive use
- Lifestyle: timing of sexual intercourse, alcohol, smoking, drugs, occupation, and stress.
- Menstrual/medical/surgical/sexual history and physical examination of both partners
- Obesity/low body weight

**Preliminary Health**
- Folate
- Rubella: If negative, vaccinate the female and wait for 1 month (RCOG)
- Thyroid
- Prolactin
- Thalassemia test of either one of the partner
- AMH and AFC are recommended and HIV, HBsAg and Anti HCV are compulsory for all

---

**Unexplained Infertility**

If age <35 years and/or good ovarian reserve

- TIC – 3–6 months
- COS + IUI – 3–6 months

If age >35 years and/or poor ovarian reserve

- IVF/ICSI
- COS + IUI – 3–6 months


---

**MALE FACTOR INFERTILITY**

Infertility is defined as the inability to conceive despite regular sexual intercourse without using contraception for one year*. 

**Preliminary Assessment**
- Age of both partners
- Duration of infertility: duration of infertility and contraceptive use
- Lifestyle: timing of sexual intercourse, alcohol, smoking, drugs, occupation, and stress.
- Menstrual/medical/surgical/sexual history and physical examination of both partners
- Obesity/low body weight

**Preliminary Health**
- Folate
- Rubella: If negative, vaccinate the female and wait for 1 month (RCOG)
- Thyroid
- Prolactin
- Thalassemia test of either one of the partner
- AMH and AFC are recommended and HIV, HBsAg and Anti HCV are compulsory for all

---

*NICE
Semen analysis
- The results of semen analysis conducted as part of an initial assessment should be compared to WHO 2010 reference value in the recommendations
- If the results of the first semen analysis is abnormal, a repeat confirmatory test should be offered ideally after 3 months or earlier, if there is a gross abnormality in semen report

**Initial Investigation & Subsequent Treatment (male)**

**Normal**
- Mild oligoteratozoospermia (>5 million/mL)
  - Antioxidants + CC + DNA fragmentation
  - Follow female algorithm

**Abnormal**
- Azoospermia / severe oligoteratozoospermia (<5 million/mL)
  - FSH - Low
    - Testosterone - Low
    - Testicular volume - Low
  - FSH - High
    - Testosterone - Low
    - Testicular volume - Low
  - Hypogonadotropic Hypogonadism (HH)
  - Hypergonadotropic Hypogonadism (HH)

See next page
1 Sperm concentration >15x10⁶/mL, motility >42%, morphology >4%

Optional

EUA update 2015
InFertility

OFFER surgical repair

Abnormal semen analysis with Normal/corrective female factors

Follow with S/A every 1 or 2 years

Young men with N S/A

ICSI

PESA, TESA, TESE

If azoospermia TESE versus Vasography if planning reconstructive surgery

If palpable Varicocele**

ICSI

Positive

Negative

TRUS

Low ejaculatory volume <1ml

Post-ejaculatory urinalysis

Obstructive

Infective

FSH – Normal
Testosterone – Normal
Testicular vol - Normal

CBAVD

Offer CFTR mutation testing to female

IF female + CFTR test male

AMH: anti-Mullerian hormone; AFC: antral follicular count; CAVD: congenital absence of the vas deferens; CC: clomiphene citrate; CT: computed tomography; CFTR: cystic fibrosis transmembrane conductance regulator; DNA: deoxyribonucleic acid; FSH: follicle-stimulating hormone; HBsAg: hepatitis B surface antigen; HCV: hepatitis C virus; HCG: human chronic gonadotropin; HIV: human immunodeficiency virus; ICSI: intracytoplasmic sperm injection; IUI: intrauterine insemination; MRI: magnetic resonance imaging; PESA: Percutaneous epididymal sperm aspiration; RCOG: Royal College of Obstetricians and Gynaecologists; TRUS: transrectal ultrasound; TESE: testicular sperm extraction; TESA: testicular / epididymal sperm aspiration; TSH: Thyroid-stimulating hormone; WHO: World Health Organization.
SCREENING IN PREGNANCY

Preface

Pregnancy is a normal physiological process and any intervention that is offered to the pregnant or expectant mother should have known benefits and should be acceptable to the woman. Screening in pregnancy is the process of surveying a population of women with markers and defined screening cut-off levels, to identify those at higher risk for a particular disorder. All pregnant women, regardless of age, should be offered, through an informed counselling process, the option of a prenatal screening test for the most common clinically significant fetal aneuploidies in addition to a second trimester ultrasound for dating, assessment of fetal anatomy, and detection of multiples.

During the entire antenatal period, clinician should remain alert to risk factors, signs or symptoms of conditions that may affect the health of a pregnant woman such as pre-eclampsia and diabetes. Screening tests assess the degree of risk, or chance, of a fetus that may potentially have certain common birth defects, but there is no certainty that the baby born will actually have the problem. If a pregnant women has a positive screening result, she should have genetic counseling and undergo one of two invasive diagnostic tests, that have greater accuracy and reliability than genetic screening alone.

The FOGSI protocol has been arrived at after careful consideration of evidences to achieve best practice for screening of women of all pregnancies and provides information for decision making about appropriate treatment in specific circumstances.
SCREENING IN PREGNANCY

(Recommended three antenatal visits, [preferable 5])
At booking general physical exam heart/lungs/breast/abdomen
In all trimesters
  • Maternal weight/BMI
  • Blood pressure/mean arterial pressure
  • Urine dipstick (albumin, sugar)

Antenatal Screening

Confirm pregnancy
  (Clinically/β HCG/ UPT/Ultrasound)

Viability Test
  (Fetal heart rate)
  (Clinical/Fetal Monitor/USG)

Pregnancy

Maternal weight

Body mass index (BMI)

Urine dipstick + All routine blood tests

Maternal blood pressure
  (both arms) (Sitting)

MAP

First -trimester

Recommended
  Wt, BP, Hb

Preferable
  Blood group and Rh (Both partners)

BMI, MAP, CBC, (Peripheral) smear, electrophoresis, HPLC

MSU + Culture
  HCV, Rubella IgG

Urine — R/M, VDRL, HpB, HIV, TSH; DIPSI

Dating Scan +NT + Dual marker + Cervical length
Screeing in Pregnancy

High risk <1:100
- NIPT
- CVS

Intermediate risk 1:101 - 1:999
- Double marker + NT + others

Low risk > 1:1000
- Reassure

Second trimester anomaly scan

BP: blood pressure; CBC: complete blood count; Hb: hemoglobin; HCV: hepatitis C virus; HPLC: high performance liquid chromatography; MSU: midstream urine; NT: nuchal translucency; R/M: routine microscopy; OGTT: oral glucose tolerance test; TSH: thyroid stimulating hormone; UPT: uterine pregnancy test; USG: ultrasonography; Wt: weight.

ANTENATAL CHECKLIST

<table>
<thead>
<tr>
<th>First Trimester</th>
<th>Recommended</th>
<th>Preferable</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weight</td>
<td>BMI</td>
<td></td>
</tr>
<tr>
<td>Blood pressure</td>
<td>Mean arterial pressure</td>
<td></td>
</tr>
<tr>
<td>Hemoglobin</td>
<td>Complete blood count/ Peripheral smear/Hb Electrophoresis/ HPLC</td>
<td></td>
</tr>
<tr>
<td>Blood group ABO &amp; Rh (both partners)</td>
<td>MSU + culture</td>
<td></td>
</tr>
<tr>
<td>Urine routine</td>
<td>MSU + culture</td>
<td></td>
</tr>
<tr>
<td>VDRL/ Hep B / HIV</td>
<td>HCV / Rubella IgG</td>
<td></td>
</tr>
<tr>
<td>TSH</td>
<td>Thyroid function test / thyroid antibodies Vitamin D</td>
<td></td>
</tr>
<tr>
<td>DIPSI test 75 gms 2 hours blood sugar</td>
<td>HbA1C / OGTT/ 6 point blood sugar test</td>
<td></td>
</tr>
<tr>
<td>Dating scan + NT Double marker (free β HCG + PAPP A1) (Contingent Screen)</td>
<td>Cervical length Uterine artery Doppler NIPT Placental Growth Factor (PLGF)</td>
<td></td>
</tr>
<tr>
<td>Per speculum exam</td>
<td>Pap smear, bacterial vaginosis and chlamydia screen</td>
<td></td>
</tr>
</tbody>
</table>

1 Low levels predict pre eclampsia
2 Low risk no further test (1:1000)
Intermediate risk (101:999) to proceed to second trimester screening vs NIPT
High risk (1:100) to go for NIPT / CVS
SECOND TRIMESTER

Pregnancy

Second-trimester (18-24 weeks)

**Recommended**
- Repeat blood tests
  - Hemoglobin
  - TSH
  - Urine dipstick
  - DPISI
  - Quadruple/triple marker
  - Anomaly scan
  - Cervical length

**Preferable**
- NIPT
- Uterine artery Doppler
- 2D-4D scan
- Fetal echocardiography

### Second Trimester

<table>
<thead>
<tr>
<th>Second Trimester</th>
<th>Recommended</th>
<th>Preferable</th>
</tr>
</thead>
<tbody>
<tr>
<td>18-24 weeks</td>
<td>Repeat bloods (Hb / blood sugar / TSH) &amp; urine test as indicated</td>
<td>NIPT</td>
</tr>
<tr>
<td></td>
<td>Quadruple OR Triple marker</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Anomaly scan</td>
<td>3D/4D scan/ Fetal Echo</td>
</tr>
<tr>
<td></td>
<td>Cervical length</td>
<td>Uterine artery Doppler</td>
</tr>
<tr>
<td></td>
<td>DIPSI screen 75 gms 2 hour blood sugar</td>
<td>6 points blood sugar HbA1C</td>
</tr>
</tbody>
</table>

Quadruple/triple marker test + Anomaly scan (18-24 weeks)

High risk >1:250
- NIPT
- Amniocentesis

Low risk (<1 : 250)
- Reassure
- Routine antenatal care

DIPSI: Diabetes in Pregnancy Study Group India; HbA1c: hemoglobin A1c; NIPT: non-invasive prenatal tests; TSH: Thyroid-stimulating hormone.
### THIRD TRIMESTER

- **Pregnancy**
- **Third-trimester**
  - 24 weeks onwards
  - **Recommended**
    - Repeat blood tests
      - Hb
      - TSH
    - Urine dipstick
    - DIPSI
    - Quadruple/triple marker
    - Anomaly scan
    - Cervical length
  - **Preferable**
    - DIPSI
    - Color Doppler
    - CTG (NST)
    - Modified biophysical profile
    - Doppler velocimetry

<table>
<thead>
<tr>
<th>Third Trimester</th>
<th>Recommended</th>
<th>Preferable</th>
</tr>
</thead>
<tbody>
<tr>
<td>24 weeks onwards</td>
<td>Repeat DIPSI screen TSH/Hb/urine</td>
<td>HbA1C</td>
</tr>
<tr>
<td></td>
<td>Growth scan with liquor volume and placental localisation</td>
<td>Fetal Doppler velocimetry</td>
</tr>
<tr>
<td></td>
<td>Fetal movement count (6 in 2 hours post-prandial)</td>
<td>CTG (NST) Modified biophysical score Doppler velocimetry</td>
</tr>
</tbody>
</table>

Preface

Menopause is a biological stage in a woman’s life marked by cessation of menstruation and associated with infertility. A woman not menstruating for one year after her last period is termed as being postmenopausal. Reduced estrogen levels associated with menopause affects the body by causing vasomotor, musculoskeletal, urogenital, and psychological symptoms. It also has a profound effect on the bone and the cardiovascular system, which can significantly affect a woman’s quality of life. Therefore, women need to know about the available therapeutic options, their risks and benefits in order to make an informed decision for effective treatment. The following flowchart helps in the diagnosis and guides the process of the management and treatment of menopause symptoms.
MENOPAUSE

- Define menopause
- Types of menopause
- Diagnosis of menopause
- Initial assessment at menopause
- Classifying women to plan management
- MHT

Retrospective diagnosis -
History of amenorrhea
>1 year
Age at menopause: In India
46.7 yrs + 4.6 yrs*

Hormonal changes: FSH and LH
Estradiol, Inhibin, AMH-
Not done routinely only in cases of POF* and To find out ovarian reserve

Presentation of patient.

Healthy with no symptoms-
assessment and management

Personal history, family
history, past history

Symptomatic -assessment

List symptoms, risk
assessment

Symptoms in woman

Symptomatic and co-morbidities -assessment

Symptoms assess co-
morbidities of diabetes,
H/T, CHD, MS, gall bladder

AMH: anti-Mullerian hormone; CHD: coronary heart disease; FSH: follicle-stimulating hormone; H/T: hypertension; LH: luteinizing hormone; MHT: menopausal hormone therapy; MS: metabolic syndrome; POF: premature ovarian failure.
MENOPAUSE DEFINITION

- Twelve months of amenorrhea
- Retrospective diagnosis
- Diminution of ovarian hormones estradiol and raised follicle-stimulating hormone (FSH) and luteinizing hormone (LH)
- No independent biological marker
- Objective sensitive marker: Irregular cycles
- Average age in India is 46.5 years and rest of world is 52 years
- Can be premature before 40 years, natural or surgical

No need to conduct tests routinely to diagnose menopause

HORMONAL CHANGES

- FSH ↑
- LH ↑
- Antimullerian hormone (AMH) ↑
- Inhibin↑
- Estradiol↓
- Estrogen becomes main hormone
- Ovaries go on producing androgens – androstenedione till 65 years↓

Routine diagnosis is by clinical history
MANAGEMENT OF HEALTHY MENOPAUSAL WOMAN WITH NO SYMPTOMS

- Education
- Counseling
- Documentation in mid-life OPD card and assessment of risk factors
- Lifestyle modifications, weight control, and nutrition
- Vitamin D 800–1200 IU
- Calcium 1200 mg
- Vitamin B12 supplementation
- Moderate alcohol, no smoking
- Exercise, aerobics, range of movement, resistance, and weight training, stretching, yoga, and meditation
SYMPTOMS IN PERIMENOPAUSE AND MENOPAUSE

**Early symptoms**
Vasomotor: Hot flashes, night sweats, mood disturbances, and irritability
Menstrual: Irregular cycles, first short and then long AUB

**Intermediate symptoms**
Musculoskeletal
Aches and pains, arthralgia
Urogenital atrophy, itching of vagina, dryness, frequency of urine, dyspareunia, and low libido

**Late symptoms**
Osteoporosis, metabolic syndrome, CHD, cancers, and Alzheimer's disease

BASIC UNIVERSAL ASSESSMENT OF ALL WOMEN IN PERIMENOPAUSE AND MENOPAUSE

Documentation in mid-life OPD card

**Personal history:**
- Last menstrual period, age of menarche
- PCOD, OH, hypertension, PIH, diabetes, CHD, fracture, thromboembolic, cancer
- Diet and physical activity,
- Sleep, sexual diseases, CKD or liver disease,
- Gall bladder or pancreas problem
- OCP use or MHT use or OCT,
- Alcohol or drug use,
- Eye or hearing problem

**Family history** of CHD, hypertension, diabetes, breast cancer, colon cancer, ovarian cancer, dementia, Alzheimer’s disease, and fragility fractures
### Physical examination
- Height
- Weight
- BMI
- Blood pressure
- Waist measurement
- Gait
- Eye
- Hearing
- Hand shake
- Breast, chest, P/A P/V / P/S
- TVS

### Investigations
- Hb, BS
- HbA1c
- TSH
- Lipid Profile
- If indicated, KFTs, LFTs
- PAP/LBC/VIA
- Mammography after 42 years or US breast
- DEXA scan if more than 5 years after menopause and earlier if risk factors

Call for re-evaluation every year and loss of height is very important.

### MANAGEMENT OF VASOMOTOR SYMPTOMS

#### General
Loose clothing, dress in layers, cool air, and avoid hot spicy food

#### Menopausal hormone therapy
Within 10 years of menopause or before 60 years of age
After counseling and assessment for risk of MHT, stroke, DVT or any other co-morbidity where MHT is contraindicated.

### CO-MORBIDITIES

#### Assess for risk factors or presence of:
- Diabetes
- Hypertension
- CHD
- Cancers and treated cancers of ovary, cervical, and endometrium
- Thyroid
- Osteoporosis
- Kidney and liver disease
- Dementia
- Gall bladder and pancreas, if symptomatic

Call for re-evaluation every year and loss of height is very important.
**MHT**

**If indicated**
- For hot flushes, night sweats, irritability, insomnia because of hot flushes
- For urogenital syndrome vaginal route
- For prevention of osteoporosis

**TYPES OF MHT**
- Estrogen alone when no uterus
- Combination of estrogen-progesterone
- Selective estrogen receptor modulators (SERMs)
- Tibolone/selective tissue estrogenic activity regulator (STEAR)
- TSEC–bezadoxiphene + CEE for osteoporosis and if risk of breast cancer
- Ospemifene for urogenital atrophy

**ROUTES OF ADMINISTRATIONS**
- Oral
- Transdermal spray
- Patches
- Gel
- Vaginal tablets
- Creams
- Intramuscular
- Intrauterine device

**HOW MHT**
- Estrogen alone continuous, if no uterus
- Estrogen+ progesterone sequential, when uterus is there – within 1 year of menopause
- Continuous combined in later menopause
- SERMS when risk of breast cancer and osteoporosis risk is there. Can cause increased hot flashes so not given before menopause.
- OCP is in POF and in AUB and contraception in perimenopause
## ESTROGENS SALTS

### Natural estrogens
- 17 β-estradiol tab (17 β-estradiol has minimal liver load as compared to estradiol valerate and CEE)
- Estradiol valerate tab
- Estrone cream
- Estriol
- CEE tablets and vaginal cream

### Synthetic estrogens
- Ethinyl estradiol is 750–1,000 times more potent than natural estrogens
- Enhances hepatic effects that increases synthesis of clotting factors, angiotensin, and SHBG

## PROGESTERONE

- Given when uterus is present, to prevent endometrial hyperplasia of because of estrogens
- Not needed when vaginal route of estrogens are given

### Types of progesterone
- Dydrogesterone
- Micronized progesterone (preferred as less thrombogenic and < risk of breast cancer)
- Levonorgestrel/IUD
- Tibolone
- Medroxyprogesterone acetate (not lipid friendly, increased risk of breast cancer)
- Cyproterone acetate, dienogest, and drospirenone (in OCP)
MHT: HOW LONG AND WHEN?

- Within 10 years of menopause and before 60 years of age
- For shortest periods for the relief of symptoms
- For hot flashes, it can be continued beyond 60 years with proper counselling
- Vaginal route daily for 2 weeks and then twice weekly for 1 year.
- If patient needs more, than it can be used for longer periods with counselling

PROGESTERONE

- Given when uterus is present, to prevent endometrial hyperplasia of because of estrogens
- Not needed when vaginal route of estrogens is given

Types of progesterone

- Dydrogesterone + estrogen (safe)
- Micronized progesterone (preferred as less thrombogenic and < risk of breast cancer)
- Levonorgestrel/IUD
- Tibolone
- Medroxyprogesterone acetate (not lipid friendly, increased risk of breast cancer)
- Cyproterone acetate, dienogest, and drospirenone (in OCP)
# DURATION OF THERAPY

### Premature menopause
- Up to natural age of menopause
- Further continuation of therapy according to the indication and need

### Natural menopause
- Safety data of EPT therapy with CEE+MPA is 3–5 years, with ET safety data for use is 7 years of treatment with 4 years follow up
- 17-β estradiol and dydrogesterone can be given 3–5 years

- MHT should begin within 10 years of menopause or <60 years of age
- Premature menopause: MHT upto natural age of menopause 3–5 years
- Continuation of therapy should be decided at the discretion of the well-informed woman and her health professional

---

# CONTRAINDICATIONS TO MHT

- Known or suspected estrogen-sensitive malignant conditions
- Undiagnosed genital bleeding
- Untreated endometrial hyperplasia
- Previous idiopathic or current venous thromboembolism
- Active or recent arterial thromboembolic disease
- Untreated hypertension
- Active liver disease
- Known hypersensitivity to the active substances of MHT or to the excipients
- Porphyria cutanea tarda (absolute contraindication)
NON-HORMONAL TREATMENTS

Non-hormonal treatments for relief of menopausal symptoms

- Gabapentin: 300 mg TID × 6 weeks–3 months
- Venlafaxine: 25–75 mg/day
- Paroxetine: 7.5–20 mg/day
- Fluoxetine: 10–20 mg/day
- Isoflavones: 70 mg–100 mg daily × 6 weeks–3 months (equal producer patients have to be identified)
- Lycopene: 18–24 mg daily
- Isoflavones, bioidentical hormones

DOSAGE OF MHT

Choice of

- Ultra low dosage
- Low dosage
- Normal dosage

EXCEPTIONS TO LOW DOSAGE

- Premature ovarian failure
- Severe osteoporosis
- Predominance of psychological problems, e.g. climacteric depression

DOSAGE

- 17 β-estradiol oral, mg/day: Ultra low dosage: 0.5, low dose: 1, normal: 2, high: 4 mg
- CEE oral, mg/day: Ultra low dosage: 0.15, low dosage: 3-4.5, normal: 0.625, high: 1.2 mg
- Estradiol valerate oral, mg/day: Low: 1, high: 2 mg
- Transdermal 17 β-estradiol μgm: Ultra low dosage: 14, low dose: 25, normal: 50, high:100 μgm
NON-ORAL TRANSDERMAL ROUTE INDICATIONS

- Transdermal estrogen has a neutral effect on triglycerides, C-reactive protein, and sex hormone binding globulin
- Triglyceridemia
- Hyperlipidemia
- Increased C-reactive protein
- Migraine
- Diabetes
- DVT
- Gall bladder disease,
- Smoking
- Controlled hypertension
- Personal preference

PROGESTERONE

- Dydrogesterone
- MPA
- Micronised progesterone
- Norethisterone
- Cyproterone acetate
- Dienogest
- Select dydrogesterone or micronized progesterone, early reports of neutral effect on breast cancer
- Metabolically friendly

Androgenic progesterone

- Blunt positive effect of estrogens on lipids, implicated in breast cancer, and CVD
- Used for hemostatic control in DUB
PROGESTERONE USE IN SURGICAL MENOPAUSE

- After endometriosis surgery with hysterectomy to take care of residual tissue
- After supracervical hysterectomy
- After ablation technique on endometrium

USE OF LEVONORGESTREL IN IUD

- During perimenopause
- Contraception
- Control of bleeding: AUB
- Women with side effects for oral progestogens

DOSE OF PROGESTERONE

- Dydrogesterone 10–20 mg/day
- For conversion of endometrium micronized progesterone 100–200 mg
- MPA 5–10 mg /day
- Levonorgestrel 0.20 mcg
- Norethisterone 1.25–2.5 mg

SERM: SELECTIVE ESTROGEN RECEPTOR MODULATORS

- A drug that acts like estrogen on some tissues but blocks the effect of estrogen on other tissues
- Used in osteoporosis, positive effect on bone
**MHT AND BREAST**

- Risk not increased in first-time hormone users [GRADE A]
- The MHT attributable risk is small and decreases when treatment stops [B]
- 17β-estradiol has negligible risk of breast cancer
- The increased risk is primarily associated with the addition of a synthetic progestogen to estrogen therapy and to duration of use [B]
- The risk may be lower with micronized progesterone or dydrogesterone [C]
- Any possible increased risk associated with MHT may be decreased by selecting women with lower baseline risk including low breast density and by providing education on preventive lifestyle measures (reducing weight, reducing alcohol intake, and increasing physical activity) [D]

**ESTROGEN-ANDROGEN COMBINATION**

- Continued VMS despite estrogen replacement
- Decreased well-being despite estrogen replacement
- Surgical menopause
- Acquired sexual desire dysfunction
- In India, androgen formulations for use at menopause are unavailable. Tibolone is a good alternative

**ENDOMETRIAL SURVEILLANCE**

- Endometrial thickness of ≤ 4 mm in TVS do not require endometrial sampling
- Endometrial thickness is > 4 mm on TVS: endometrial sampling
- Endometrium thickness ≥6 mm on TVS with homogeneous and normal morphology, women on hormonal therapy and hypertensive medication is acceptable
- Homogenous endometrium and local thickening even with thin endometrium needs investigation by Pipelle aspirations and HPE or hysteroscopy directed biopsy
INDICATIONS FOR DEXA SCAN

- All women 5 years beyond the age of natural menopause
- Women less than 5 years since menopause with a particular risk factor
- Women with fragility fractures
- Women in menopause transition with secondary causes
- Radiological evidence of osteopenia and presence of vertebral compression fractures
- Before initiating pharmacotherapy for osteoporosis
- The interval testing should be based on calculated individual risk, mostly be scheduled between 1 and 5 years later

VENOUS THROMBOEMBOLISM AND MHT

- Oral estrogen is contraindicated in women with a personal history of VTE [A]
- Transdermal estrogen should be first choice in obese women with VMS [B]
- VTE risk increases with age and with thrombophilic disorders
- The risk of VTE increases with oral MHT but is rare below 60 years of age
- Two times more VT risk is associated with CEE*

WE DON'T NEED THROMBOPHILIA PROFILE BEFORE STARTING MHT

CHECK LIST

- Mid life OPD card
- Breast self exam card
- Cuscos speculum and light
- Cx cancer screening kits
- 5% Acetic acid
- Colposcope (if possible)

## RISK FACTORS FOR OSTEOPOROSIS

<table>
<thead>
<tr>
<th>Non modifiable</th>
<th>Modifiable</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female</td>
<td>Physical activity: muscle building exercises</td>
</tr>
<tr>
<td>Menopause</td>
<td>BMI</td>
</tr>
<tr>
<td>H/O fragility #</td>
<td>Smoking</td>
</tr>
<tr>
<td>H/O fragility# in family</td>
<td>Alcohol &gt;3 drinks/day</td>
</tr>
</tbody>
</table>

## RISK OF DVT

- Previous history of DVT during pregnancy, prolonged bed rest or surgery
- High risk profession like air hostess
- Personal history or family history
- Known thrombophilia (F5 Leiden, Protein C, antithrombin III)

## RISK OF DIABETES MELLITUS

<table>
<thead>
<tr>
<th>Non modifiable</th>
<th>Modifiable</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypertension</td>
<td>Advancing age</td>
</tr>
<tr>
<td>Dyslipidemia</td>
<td>Endogenous estrogens</td>
</tr>
<tr>
<td>Polycystic ovary syndrome</td>
<td>Late menopause</td>
</tr>
<tr>
<td>Physical inactivity</td>
<td>Nulliparity and Infertility</td>
</tr>
<tr>
<td>Obesity</td>
<td>Genetic factor</td>
</tr>
</tbody>
</table>
### RISK OF ALZHEIMER

<table>
<thead>
<tr>
<th>Modifiable</th>
<th>Non modifiable</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical inactivity</td>
<td>Age</td>
</tr>
<tr>
<td>Diabetes</td>
<td>Family history</td>
</tr>
<tr>
<td>Hypertension</td>
<td>Genetic factor apolipoprotein (APOE)</td>
</tr>
<tr>
<td>Dyslipidaemia</td>
<td>Auto-immune diseases</td>
</tr>
<tr>
<td>Smoking</td>
<td>Head trauma</td>
</tr>
<tr>
<td>Obesity</td>
<td>Traumatic brain injury</td>
</tr>
<tr>
<td>Depression</td>
<td></td>
</tr>
<tr>
<td>Stress &amp; social engagement</td>
<td></td>
</tr>
<tr>
<td>Diet</td>
<td></td>
</tr>
<tr>
<td>Poly pharmacy and thyroid medications</td>
<td></td>
</tr>
</tbody>
</table>

### RISK OF BREAST CANCER

<table>
<thead>
<tr>
<th>Modifiable</th>
<th>Non modifiable</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at first child</td>
<td>Age and gender</td>
</tr>
<tr>
<td>Breastfeeding</td>
<td>Benign breast disease</td>
</tr>
<tr>
<td>BMI</td>
<td>Family history of inherited cancers</td>
</tr>
<tr>
<td>Alcohol</td>
<td>BRCA1 &amp; BRCA2</td>
</tr>
<tr>
<td>Hormone Therapy?</td>
<td>Menstrual history: Ages at menarche and menopause</td>
</tr>
<tr>
<td></td>
<td>Breast density on mammogram</td>
</tr>
<tr>
<td></td>
<td>Medical history of Hodgkin's lymphoma</td>
</tr>
</tbody>
</table>
### RISK FACTORS OF ENDOMETRIAL CANCER

<table>
<thead>
<tr>
<th>Modifiable</th>
<th>Non Modifiable</th>
</tr>
</thead>
<tbody>
<tr>
<td>Obesity</td>
<td>Advancing Age</td>
</tr>
<tr>
<td>Diabetes</td>
<td>Endogenous estrogens</td>
</tr>
<tr>
<td>Hypertension</td>
<td>Late menopause</td>
</tr>
<tr>
<td>Polycystic ovarian syndrome</td>
<td>Nulliparity and infertility</td>
</tr>
<tr>
<td>Unopposed estrogen therapy</td>
<td>Genetic factor</td>
</tr>
</tbody>
</table>

### BIBLIOGRAPHY

1. ACOG, Clinical management guidelines for obstetrician gynecologists number 141, January 2014.

Preface

Immunization of a pregnant woman enables a number of important health benefits for both mother and the baby. Vaccine-preventable diseases have been shown to cause significant morbidity and mortality among maternal, neonatal, and young infant. Furthermore, some of these infections can be serious enough to waste pregnancy, or affect the infant post delivery.

Vaccination of the pregnant women has been shown to strengthen her immune systems to fight off serious infectious diseases. It helps in protecting the mother from infections and this immunity passes to her infant during pregnancy, keeping the child safe during the first few months of life.

The fear that fetus can be at risk after vaccination of the mother during pregnancy has no scientific bases. There have been no study to show if there is risk for fetus after maternal vaccination with inactivated vaccines or bacterial vaccines or toxoids. Since live vaccine poses a theoretical risk to a developing fetus, all live vaccines should be avoided during pregnancy.

Lack of awareness of risk and benefits of vaccination during pregnancy is a common barrier for its use.
Vaccination in Adult Women

Adolescents

- HPV

Pre-pregnancy

- Rubella

Pregnancy

- Refer table below

Post-natal/Lactation

- Refer next page

Older women

- Refer next page

**Human papilloma virus (HPV)**

- Licensed 9–45 years (bivalent and quadrivalent)
- Ideally administered before sexual exposure:
  - If <15 years: 2 doses (0 and 6 months)
  - If >15 years or immunocompromised:
    - 3 doses (0, 1 / 2 and 6 months)
  - Cervarix: 0, 1 and 6 months
  - Gardasil: 0, 2 and 6 months
- Counsel to AVOID pregnancy for 4 weeks after vaccine administration
- HPV testing not necessary before vaccination.

**Rubella**

- Vaccination history; H/o Rubella
- Check Rubella IgG whenever possible
- Single dose Rubella vaccine or MMR vaccine
- Counsel to AVOID pregnancy for 4 weeks after vaccine administration
- Thereafter, no need to check antibody titre

**Varicella**

- Vaccination history; H/o varicella
- 2 doses: 0 and 1 month
- Counsel to AVOID pregnancy for 4 weeks after vaccine administration.

**All vaccines are optional**

- FOGSI recommends HPV vaccination inn all adolescents for protection against cancer of cervix

---

### PREGNANCY

<table>
<thead>
<tr>
<th>Strongly recommended</th>
<th>Recommended</th>
<th>Not recommended</th>
</tr>
</thead>
<tbody>
<tr>
<td>TT: 2 doses or Tdap</td>
<td>Influenza vaccine (during flu season) Intramuscular after first trimester</td>
<td>HPV MMR Varicella</td>
</tr>
<tr>
<td>TT</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1st dose: Between 16–20 weeks, 2nd dose: After 4–6 weeks after the 1st dose.</td>
<td></td>
</tr>
<tr>
<td>Tdap</td>
<td>Can replace TT (wherever available)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Single dose replaces both doses of TT: Administered 28–36 weeks, if previously immunized</td>
<td></td>
</tr>
<tr>
<td></td>
<td>If not immunized: 2 doses of TT and 1 dose of Tdap.</td>
<td></td>
</tr>
</tbody>
</table>
Recommended vaccines under “Special Situations”

- Rabies: Where the benefits outweigh the risks involved
- Hepatitis A
- Hepatitis B
- Cholera
- Typhoid

COUNSELLING

- The lady must be counseled properly clearly explaining the benefits and side-effects of the concerned vaccine; consent must be obtained.
- AEFI (Adverse Events Following Immunization) reporting: Risk of anaphylaxis must be explained.

ADVERSE EVENTS FOLLOWING IMMUNIZATION

- Mild reactions (common): Injection site pain, redness, swelling, induration.
- Moderate reactions (occasional): Fever, headache, myalgia, joint pains, lymph node swelling, and gastrointestinal disorders.
- Severe reactions (rare): Circulatory reactions, chills, paresthesia, allergic reactions, and anaphylaxis.

HPV: human papillomavirus; IgG: immunoglobulin G; MMR: Measles, mumps, and rubella.

Documentation must be made regarding that the “patient and accompanying relatives, if present, were properly counseled about the potential benefits and risks of the vaccine prior to administration.”
Preface

Hypertensive disorders during pregnancy (HDP) are a major cause of maternal morbidity and mortality and are known to complicate about 3-10% of all pregnancies. About 10-15% of all maternal deaths are contributed by hypertensive disorders of pregnancy especially in the developing world.

Preeclampsia and eclampsia has been seen to occur, most often after 20 weeks of gestation.

A noteworthy feature is that the prevalence of hypertension during pregnancy has been seen to be significantly higher in women with previous history of cesarean section (17.6 vs 6.5%) as compared to women with no history of cesarean section. A significantly higher rate of prior cesarean section were recorded in women with chronic hypertension as compared to normotensive women.

The complications of HDP which are responsible for maternal morbidity and mortality include cerebro-vascular accidents, acute renal failure and pulmonary edema, all of which are potentially preventable. So, the need of the hour is to enable an effective screening strategy to diagnose hypertension during pregnancy and also to device a comprehensive protocol for management of such cases.
# Hypertensive Disorders in Pregnancy (HDP)

## Classification
- Gestational Hypertension
- Preeclampsia/eclampsia
- Chronic hypertension
- Preclampsia superimposed on hypertension

## Prevention and Prediction
- Risk Identification: age >40; < 20
- BMI >30
- Family history of preeclampsia
- Inter-pregnancy interval >10 yrs
- Nulliparity
- H/O Prev HDP, CKD, diabetes, APLS, Autoimmune disease
- Multiple pregnancy
- Gestational trophoblastic disease

Prevention by:
- Low Dose Aspirin from 12 weeks
- Calcium supplementation 1 gm BD

Prediction uterine artery Doppler in high risk cases

## Diagnostic Evaluation
- Signs: Hypertension
  - Rapid weight gain
  - Progressive edema
- Warning S/S:
  - Headache
  - Epigastric pain
  - Visual disturbances
  - Oliguria
- Proteinuria/protein: creatinine ratio in urine
- Full blood count with platelets
- Urea, creatinine electrolytes
- LFT including LDH

Categorize: Non severe severe
Hypertensive Disorders in Pregnancy (HDP)

**Non-Severe**

- Systolic 140–159 mmHg
- Diastolic 90–109 mmHg

- Expectant management up to 37 weeks in absence of
  - Organ involvement
  - Thrombocytopenia
  - HELLP syndrome
  - Symptoms of cerebral irritation
  - Abruption
  - Fetal compromise
- Anti hypertensive drugs, if required

**Monitoring**

**Maternal**

- B P frequently till stable
- Full blood count
- Urea, creatinine electrolytes
- LFT including LDH
- Evaluate progress and severity of organ involvement

**Fetal**

- Daily fetal kick count
- NST
- USG for fetal growth and wellbeing

**Severe**

- Systolic ≥ 160 mmHg
- Diastolic ≤ 110 mmHg

- Serum creatinine >1.1 mg/dl
- Oliguria
- Pulmonary oedema
- Epigastric/RUQ Pain
- Impaired LFT (SGPT levels twice normal)
- Thrombocytopenia, platelets <100,000/μL
- Headache, visual disturbance, convulsions

**Management**

- Multidisciplinary team approach
- Hospitalization and Monitoring
- Prophylactic magnesium sulphate
- Antihypertensives
- Strict I/O chart
- Maternal and fetal assessment

**Non-Severe**

**Severe**

**Monitoring**

**Maternal**

**Fetal**

**Non-Severe**

**Severe**

**Non-Severe**

**Severe**

**Non-Severe**

**Severe**

**Non-Severe**

**Severe**
**HYPERTENSIVE DISORDERS: OBSTETRIC MANAGEMENT**

**Non-Severe**
- ≥ 37 weeks gestation: deliver
- < 37 weeks gestation: individualize and deliver
- Abnormal fetal Test results, Fetal growth restriction

Worsening of fetal /maternal condition
- Steroids
- Deliver

**Severe**
- < 26 weeks: stabilize and deliver
- 26-34 weeks: expectant management: Steroids neuroprotection by magsulfate sulfate and deliver
- > 34 weeks: Stabilize and deliver

**Delivery Indications**
- Maternal
  - Severe disease
  - Imminent eclampsia
  - HELLP syndrome
  - Abruptio

- Fetal
  - Severe FGR
  - Poor NST
  - Fetal compromise

**SEVERE HDP: COMPLICATIONS**
**REQUIRES MULTI DISCIPLINARY MANAGEMENT**

- Eclampsia
- HELLP syndrome
- Neurological complications
- Pulmonary edema
- Acute kidney injury
- Peripartum cardiomyopathy
- Disseminated intravascular coagulation
- Multi-organ failure
HYPERTENSIVE DISORDERS IN PREGNANCY (HDP)

HDP: MANAGEMENT: ANTIHYPERTENSIVE DRUG

**Non-Severe**

Start drugs when DBP >100 mm Hg

- Tab Labetalol 200 mg 6 to 8 hourly
- Tab Nifedipine 10 to 20 mg thrice a day
- Tab Metyldopa 250 to 500 mg 6-8 hrly

If available and patient is already having it, can be stopped if BP controlled with above drugs.

**Severe**

Avoid drastic and sudden lowering of BP.

Maintain DBP: 90-100 mm Hg

Systolic DBP >110 mm Hg

- Inj Labetalol
- Tab Nifedipine
- Inj Hydralazine

- Inj Labetalol: 20 mg IV, if no response then 40-80 mg every 20-30 min, max of 220 mg: for infusion: 1-2 mg/min
- Hydralazine (5 mg IV bolus then if needed, 5-10 mg IV every 10-20 min to a maximum of 45 mg) (FIGO 2016)
- Nifedipine tablet (10 mg orally every 20-30 min to a maximum of 30 mg) (FIGO 2016)

**NOTE:**

- No sublingual Nifedipine
- No Frusemide
- Avoid drastic and sudden lowering of BP.
- Can use Nifedipine + Magnesium sulphate, but with caution
- Prior to transfer to tertiary care start IV line and give Inj magnesium sulphate

APLS: antiphospholipid antibodies; BP: blood pressure; CBC: complete blood count; CRP: C-reactive protein; CKD: chronic kidney disease; DBP: diastolic blood pressure; FGR: fetal growth restriction; HDP: hypertensive disorders of pregnancy; HELLP: Hemolysis, elevated liver enzymes, low platelet count syndrome; LDH: lactate dehydrogenase; LFT: liver function tests; LSCS: lower (uterine) segment Caesarean section; NST: Non-Stress test; RFT: renal function tests; RUQ: right upper quadrant; SGPT: serum glutamic pyruvic transaminase; USG: ultrasonography.
MANAGEMENT OF A PREGNANT WOMAN PRESENTING WITH ECLAMPSIA

**Shout for help! IV access (no.16 to 18 cannula)**

- Place woman on her left side to reduce risk of aspiration of secretions, vomitus and blood

**Assess breathing**

- Simultaneously, take patient’s history from relatives
- Post convulsion: clean mouth and throat, continue IV infusion at maximum of 80 ml/hr. Catheterize patient and I/O chart

**Check airway and intubate, if required**

- Rapidly evaluate vital sign (pulse, BP, and temperature). If pulse not palpable, CPR initiated, and resuscitate
- If breathing, given oxygen at 4-6 L/min by mask or nasal cannulae. Examine neck for rigidity

**Investigation:**
- Blood group, CBC with platelets, sugar, LFT, RFT

**Start Magnesium sulphate**

- Magnesium sulfate loading dose: 4 g IV as 8 ml of 50% solution diluted in 12 mL saline over 5 minutes. 10 gm of 50% solution, 5 g in each buttock as deep IM injection (can add 1 mL of lignocaine in same syringe. Maintenance dose of 5 gms IM 4 hourly on alternate buttock

**Start anti hypertensive drugs if diastolic BP>100 mmHg**

- Labetolol -10-20 mg IV, then 20-80 mg every 20-30 min, max of 220 mg; for infusion: 1-2 mg/min
- Nifedipine 10-30 mg PO, repeat in 45 min if needed
- Hydralazine Inj. 5 mg IV or IM, later 5-10 mg every 30 min once BP is controlled repeat every 3 hours to a max 5 doses

**Provide ongoing care**

- Monitor vital sign (pulse, BP & respiration > 16/min), patellar reflexes and urinary output > 30ml/hr
- Maintain strict fluid balance chart to prevent fluid overload.
- Provide maintenance dose of anti-convulsive and anti-hypertensive drugs
- Auscultate lung base hourly for rales (indication of pulmonary edema)
- Plan delivery, Monitor progress of labour, LSCS for obstetric indication
Preface

Postpartum hemorrhage is generally considered as ≥500 ml of blood loss within 24 hours after birth, while severe PPH is blood loss ≥1000 ml within 24 hours. It is the most common cause of maternal death worldwide. Most cases of PPH associated morbidity and mortality occur in the first 24 hours following delivery, whereas other few cases of PPH also occur due to abnormal or excessive bleeding from the birth canal between 24 hours and 12 weeks postnatally. Blood loss post-delivery is rarely measured in clinical practice, hence there is lack of clarity. Measuring blood loss may improve the care and outcome for women. Grand multiparity and multiple gestations are known risk factors for PPH. Moreover, it may occur in women without identifiable clinical or historical risk factors. Therefore, it is recommended that active management of the third stage of labor should be offered to all women during childbirth. Preventing delays in the diagnosis and treatment improves the chances of survival. The following demonstrates the “care pathway” for management of PPH, as a practical guide for clinicians.
POSTPARTUM HAEMORRHAGE (PPH)

**Definition**
Any bleeding after the delivery of a baby that may affect the hemodynamic status/vital parameters of the mother.

Blood loss: Vaginal delivery >500 ml; caesarean section >1000 ml

**Types**
- Early
- Late (primary/secondary)

*PPH can occur without any risk factor

**Prevention of PPH**

- Correct antenatal anemia
- Look for risk factors*
- Active management of third stage labour

Oxytocin 10 units in 1 min/5 units IV
- Delayed cord clamping
- Controlled cord traction with uterine palpation
- Inspection of lower genital tract and placenta

*PPH can occur without any risk factor
MANAGEMENT OF POST-PARTUM HEMORRHAGE

All components should be carried out simultaneously. Try to establish cause of PPH.

**Prevention of PPH**

- Communication
  - Inform patient and relatives
  - Call for Help obstetrician and anaesthetist
  - Alert OT, ICU, Blood bank

- Assessment
  1. **Clinical**
     - Pulse, BP,
     - Respiratory rate
     - Input/output
  2. **Assess Blood Loss**
     - CBC
     - Grouping and cross matching
     - Bedside clot testing
     - Coagulation studies
     - Platelet count
     - PT - INR
     - aPTT
     - Fibrinogen
     - Renal and liver functions

- Resuscitation
  - ABC approach
  - 100% oxygen at 10-15 L/min
  - 16 G cannula x 2
  - Urinary catheter

- Replace
  - 3.5 L of warmed fluid initially
  - 2L crystalloid followed by crystalloid/colloid
  - Blood transfusion group specific/ O -ve
  - Coagulation factors
    - FFP
    - Cryoprecipitate
    - Platelets
  - Massive transfusion protocol (MTP)

- Arrest
  - Uterine massage
  - Bimanual uterine compression-AORTIC Compressium
  - Drugs
    - Uterotonics
      - Oxytocin
      - 10U IM / 5U IV followed by 20–40U IV in 500–1000ml at 125mL/hr
      - Ergometrine every 5 mins, 5 doses, 0.25–0.5mg IV/mcg IM
      - Misoprostol 400–800 mcg rectal
      - Carboprost 0.25 mg IM every 15 mins, max 8 doses
    - Tranexamic acid 1g IV
    - Surgical intervention
      - Removal of retained placenta
      - Repair of tears
      - Uterine packing
      - Balloon tamponade
      - Brace sutures
      - Step in devascularisation
      - Arterial embolization
    - Hysterectomy

aPPT: activated partial thromboplastin time;
BP: blood pressure; CBC: complete blood count; FFP: fresh frozen plasma; ICU: intensive care unit; OT: operation theater; PT-INR: prothrombin time-and international normalized ratio.
Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in women of reproductive age with prevalence estimates ranging from 2.2% to as high as 26%. This syndrome is a common disorder complicated by hyperandrogenism and chronic anovulatory infertility associated with clinical manifestations of oligomenorrhea, hirsutism, and acne.

Women having PCOS are generally obese, exhibit an adverse cardiovascular risk profile, and have a higher prevalence of impaired glucose tolerance, type II diabetes, and sleep apnoea. These patients are also prone to high incidence of cardiometabolic syndrome involving hypertension, dyslipidaemia, visceral obesity, insulin resistance, and hyperinsulinaemia. Gynaecologists are observed to frequently diagnose PCOS; therefore in order to offer a holistic approach to the disorder, it is essential to have a good understanding of the long-term implications of the PCOS diagnosis. The healthcare professionals need to educate the women with PCOS regarding the possible long-term health risks and positive effects of lifestyle modifications. Those with PCOS before pregnancy should be diagnosed for gestational diabetes. The algorithm provided in this chapter guides through the process of diagnosis, investigations and management of adolescents, women and postmenopausal women with PCOS.
POLCYSTIC OVARY SYNDROME

PCOS

- Commonest endocrinopathy of reproductive age group
- Worldwide prevalence of 5–15%
- Four phenotypes
- Major symptoms related to hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology

Adolescent PCOS

Adult PCOS

- Perimenopausal
- Menopausal
- PCOS

Seeking fertility

Not seeking fertility

- Diagnosis
- Investigations
- Management
- Long-term consequences
- Follow up
POLCYSTIC OVARY SYNDROME

Adolescent PCOS

Diagnosis

- Presence of oligo/ Amenorrhoea (OD) >2 years of menarche
- All the three criteria- OD, Hyperandrogenism, PCOM must be present
- PCO with strict interpretation of ultrasonography findings

Investigation

- Minimal 5 biochemical tests required-Grade A, Evidence level-4
  - Serum TSH, FSH, LH, Prolactin (to rule out other causes)
  - Serum total testosterone < 60 ng/dl
  - Serum 17(OH) progesterone at 8 am
  - OGTT (at zero and 2 hours after 75 g glucose load)

Management

- Lifestyle modification in combination with balanced but hypocaloric diet x 6 months- 1st line treatment.
  - Grade-B, Evidence level-4 daily strict physical activity sessions for at least 30 min/day or 150 min/ week are recommended (Grade A, EL 4).
  - Add metformin as second-line therapy for weight loss.
  - Grade-B, Evidence level-4
  - Other insulin sensitizers like inositol group can be tried (Myoinositol plus D-chiro-Inositol).

Low dose COCs-next line of management.
Grade A, evidence level-4
- Use low-dose COCs (with or without anti-androgenic progestins- drospirenone and desogestrel) for the management of MI (Grade A, EL 4)
- Between 12-16 years of age, low-dose COCs only to be used, for short period (up to 7 days
- After 16 years of age long-term therapy accepted
- The duration of COCs to treat hyperandrogenism is not established yet
- A break of 3 months every one year is recommended to prevent thromboembolic events

Pharmacological treatment

Progesterone withdrawal bleed- First line therapy
Grade A, Evidence level-4
Aim is to give minimum 4 bleed per year.
Selection of COCs may be decided on the nature of predominant symptoms

- **Menstrual irregularity**
  - Obese
    - EE + drospirenone better suited than other third generation pills
  - Non-obese
    - EE + any third generation progesterone

In case of non-tolerance and contraindication to COCs, metformin can be used along with or without cyclic progesterone bleed.

**Grade A, Evidence level 4**
- Myo-inositol + D-chiro-inositol improve insulin sensitivity, body mass index (BMI), and menstrual irregularities

- **Hirsutism**
  - EE + Cyproterone acetate (combination preferred) + temporary hair removal methods x 6 months.
  - 1st line therapy
    - **Grade A, evidence level 1**
  - Add spironolactone/fenastride- if no desired response or poor tolerance
    - **Grade A, Evidence level 2**
  - Treatment has to be stopped 6 months before trying for pregnancy
  - Other permanent methods of hair removal therapies
  - There is no role of metformin in treating hirsutism until the adolescent has a deranged GTT
  - Myo-inositol + D-chiro-inositol improve hyperandrogenism
  - Adjuvants like omega 3 fatty acids or alternative therapies (acupressure etc) – evidence is inconclusive

- **Acne/alopecia**
  - COCs with anti-androgenic progesterone activity (drospirenone, desogestrel, cyproterone acetate) along with treatment based on clinical presentation and a dermatologist’s opinion.

First-line therapy

**Grade A, Evidence level 1**
- Cyproterone was found to be better suited for Indian population.
Adult PCOS

Diagnosis
- Rotterdam’s criteria-2/3
- FSH, LH, TSH, E2 and prolactin to rule out other causes
- Biochemical determination of testosterone. Grade, Evidence level 4
- AMH Grade B, Evidence level 4
- 17 hydroxy progesterone in obese and hirsute
- Progesterone withdrawal bleeding Grade B, evidence level 4

Ovulation induction

Seeking fertility
- Regular follow-up for metabolic syndrome, carcinoma risk
- Life style modifications- with targeted weight reduction of at least 5–10% and preventing further gain. Grade A, EL1
- By calorie restricting diet (500 calories) and physical activities 60 minutes/day along with control of other factors (alcohol consumption, excessive coffee intake, cessation of smoking) for 3 months.
- The age-related decline in fertility should be given appropriate consideration for considering the duration of lifestyle management interventions (Grade B, EL 4).
- In morbidly obese women (BMI >35) no OI before improvement in BMI. Orlistat can be given up to 3 months.
- In obese women, myoinositol + D-chiro-Inositol (40:1) for 6 months
- Bariatric surgery- first line in BMI >50, second line in BMI >35
- Positive role of yoga

Pre-conception counseling
- Positive counseling
- Counseled on the need for identification and correction of long-term risk factors affecting fertility before initiating treatment (Grade A, EL 4).
- Regarding diet, lifestyle, cessation of smoking, and folic acid intake.
- PCOS women with subfertility should be counseled on length of procedure, types, side effects, success rate, and cost of treatment (Grade B, EL 4).

Not seeking fertility
- Lifestyle modification by diet and exercise (like in adolescents)
- Identification of metabolic syndrome markers and treat them properly.
- Menstrual irregularities also to be treated similarly as adolescents.

Lifestyle modification by diet and exercise (like in adolescents)
- Identification of metabolic syndrome markers and treat them properly.
- Menstrual irregularities also to be treated similarly as adolescents.

Regular follow-up for metabolic syndrome, carcinoma risk
- Life style modifications- with targeted weight reduction of at least 5–10% and preventing further gain. Grade A, EL1
- By calorie restricting diet (500 calories) and physical activities 60 minutes/day along with control of other factors (alcohol consumption, excessive coffee intake, cessation of smoking) for 3 months.
- The age-related decline in fertility should be given appropriate consideration for considering the duration of lifestyle management interventions (Grade B, EL 4).
- In morbidly obese women (BMI >35) no OI before improvement in BMI. Orlistat can be given up to 3 months.
- In obese women, myoinositol + D-chiro-Inositol (40:1) for 6 months
- Bariatric surgery- first line in BMI >50, second line in BMI >35
- Positive role of yoga

Diagnosis
- Rotterdam’s criteria-2/3
- FSH, LH, TSH, E2 and prolactin to rule out other causes
- Biochemical determination of testosterone. Grade, Evidence level 4
- AMH Grade B, Evidence level 4
- 17 hydroxy progesterone in obese and hirsute
- Progesterone withdrawal bleeding Grade B, evidence level 4

Ovulation induction

Seeking fertility
- Regular follow-up for metabolic syndrome, carcinoma risk
- Life style modifications- with targeted weight reduction of at least 5–10% and preventing further gain. Grade A, EL1
- By calorie restricting diet (500 calories) and physical activities 60 minutes/day along with control of other factors (alcohol consumption, excessive coffee intake, cessation of smoking) for 3 months.
- The age-related decline in fertility should be given appropriate consideration for considering the duration of lifestyle management interventions (Grade B, EL 4).
- In morbidly obese women (BMI >35) no OI before improvement in BMI. Orlistat can be given up to 3 months.
- In obese women, myoinositol + D-chiro-Inositol (40:1) for 6 months
- Bariatric surgery- first line in BMI >50, second line in BMI >35
- Positive role of yoga

Pre-conception counseling
- Positive counseling
- Counseled on the need for identification and correction of long-term risk factors affecting fertility before initiating treatment (Grade A, EL 4).
- Regarding diet, lifestyle, cessation of smoking, and folic acid intake.
- PCOS women with subfertility should be counseled on length of procedure, types, side effects, success rate, and cost of treatment (Grade B, EL 4).
Medical management

- Clomiphene citrate (CC) - first line option for OI. dosage 50-150 mg x 3-6 cycles, with per cycle increment of 50 mg.
- Ultrasound monitoring with CC recommended to see the response and reduce the chances of multiple gestation and hyper-stimulation.
- In unavailability of USG, LH kit monitoring recommended.

Lodotropin / CC resistance / no conception

- Letrozole / AI - 2.5 - 5 mg/ day for 3-6 cycles
- Best response in non-obese PCOS
- And hyper LH PCOS.
- CC failure
- Gonadotropin failure
- Very soon may replace CC as first-line management of OI?

CC failure / CC resistance / no conception

- Not a first line management
- Recommended mode in women with CC resistance and hyper LH PCOS, before gonadotropin stimulation.
- Number of punctures according to the size of ovaries but not to exceed 4-6 holes/ovary. Grade B, Evidence level 4
- No other factor contributing to infertility should be present.

Gonadotropins are second line of treatment for CC failure, CC resistance
Chronic low dose or low dose step-up protocol preferred. Minimum starting dose 37.5 IU to 75 IU. With weekly increment of 50% dose till the lead follicle reaches 12 mm, then same dose to be continued till trigger x 3 cycles. Counseling regarding increased cost, strict monitoring, cancellation of cycle, hyperstimulation and multifetal gestation. Grade A, evidence level 2

Pretreatment with combined oral contraceptive pills
Low dose combined COCs pretreatment (with/without lifestyle modifications) for at least 2 months is recommended in subfertile PCOS patients with high LH level (3 times the basal levels) to normalize it (Grade B, EL 4).

Melatonin, N-acetyl cysteine (NAC), and myo-inositol have emerged as novel pharmacotherapeutics to improve IVF outcomes for the treatment of infertility. Myo-inositol + folic acid for 3 month*

CC/letrozole + gonadotropin

ART: a third line treatment option in women with PCOS who fail to conceive or who have other indications for IVF (Grade A, EL 2).
Myo-inositol plus D-chiro-inositol increases oocyte, embryo quality, and pregnancy rates."

IUI

- Not a routine treatment for PCOS only.
- Recommended in PCOS with mild male factor subfertility.
- PCOS women ovulating with drugs but not conceiving normally.

Luteal phase support - Progesterone is recommended in sub-fertile PCOS women undergoing OI or assisted reproduction (Grade A, EL 2)
Myo-inositol 2 g + folic acid 200 mg twice daily.*
**Diagnosis**
- Difficult to diagnose, at least two criteria must present (hyperandrogenism with menstrual dysfunction)
- PCOM if present has added advantage

**Investigations**
- OGTT
- Lipid profile
- Total testosterone
- Carotid intima thickness
- Thyroid profile
- Investigations related to metabolic disease risk.
- TVS/HPE endometrium

**Management**
- Life style modifications
- Insulin sensitizers and adjuvants
- Myoinositol + D-chiro-inositol improves glucose metabolism, which in turn improves lipid profile and reduces cardiovascular risk.
- Peri-menopausal women with menstrual irregularities have to be treated like any other adult.
- Multidisciplinary approach has to be adopted for various cardio-metabolic complications.

**Sleep apnea and depression**
- Proper history of sleep apnea to be taken, like day time sleepiness, laziness etc
- Due to higher tendency of depression and anxiety, history to be taken and proper behavioral and expert therapy to be recommended

**Follow-up recommendations**
- Blood pressure monitoring yearly in non-hypertensive PCOS
- OGTT every year in non-diabetic normal PCOS
- Abnormal GTT- as per requirement
- Cardiovascular risk- not to be done routinely in absence of any other high risk factor or family history

---


AI: Aromatase Inhibitor; AMH: anti-Mullerian hormone; BMI: body mass index; COCs: combined oral contraceptive; E2: estradiol; EE: ethinylestradiol; FSH: follicle-stimulating hormone; GTT: glucose tolerance test; HPE: histopathological evaluation; IVF: in-vitro fertilization; LH: luteinizing hormone; LOD: laparoscopic ovarian drilling; OGTT: oral glucose tolerance test; OI: Ovulation Induction; PCOM: polycystic ovarian morphology; TSH: Thyroid-stimulating hormone; TVS: Transvaginal sonography; USG: ultrasonography.
Preface

Unintended pregnancies have significant social and economic consequences. The effectiveness of different currently available methods in preventing pregnancy varies widely. It is generally accepted that long-acting reversible contraceptives (LARCs), including intrauterine devices (IUDs), and progestogen implants, are most effective apart from permanent sterilization methods such as vasectomy and tubal ligation. LARCs are safe and highly effective for women in reducing unintended pregnancy and abortion rates due to their long duration of action and requirements of minimal adherence.

Ovulation occurs at a mean of 39 days post-partum in non-lactating women, which increases the risk of unintended and short-interval pregnancy. Around 70% of pregnancies are unintended during the first year post-delivery. Therefore, use of reversible contraceptive methods can provide several potential benefits and help in lowering the rate of unintended pregnancy and avoiding short-interval pregnancy.

Before selecting a post-partum reversible contraceptive method, women should be counseled prenatally, including counseling regarding the advantages, risks of IUD expulsion, as well as contraindications. Therefore, LARCs are recommended as effective means of contraception without its impact on future fertility. The algorithms provide a process for availability, methods, and selection of modern contraceptive options.
**Selection of Modern Contraceptives**

Need for spacing?

Preferred route and duration?

**Oral**

**Short-term reversible**
- Hormonal
- Combined
- Progesterone
- As back-up, EC
- Extended use-algorithm for OCS

**Non-Oral**

**Long-acting reversible**

Administered by whom?

**Self**

- Vaginal ring
  - Combined hormonal
  - Progestogen only
  - Transdermal patch*
  - Injectable SC

**Medical/Paramedical/Midlevel practitioner**

- Limited duration
  - Injectable
    - Progestogen only DMPA

- Extended duration
  - IUD
    - Non hormonal Copper
      - Short duration
      - Extended duration
    - Hormonal LNG-IUS
  - Implants

*Desire for regular cycles
Long-acting reversible contraception (LARC)

<table>
<thead>
<tr>
<th>Time of use / administration</th>
<th>IUD</th>
<th>Injectables</th>
<th>Copper</th>
<th>LNG</th>
<th>Implant</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interval</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Post abortal</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Post partum</td>
<td></td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>Emergency</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*6 weeks postpartum if lactating.

Options for Contraception

**LARC methods**

**Non LARC Hormonal**

- Efficacy compliance
  - Consider alternative if patient is on enzyme inducers

**Barriers**

- Less reliable
  - Condoms protect from STI
  - Risk is minimal (MEC)

**Condoms**

- Male
- Female
- Not available

**Diaphragm**

- with spermicide
- HCP needed
- Not available

**Intrauterine**

- Copper IUD
  - 5-10 yrs life
  - Heavier, longer painful periods
  - Useful in postpartum and postabortal cases

- Hormonal IUD
  - 5 yrs life
  - Lighter bleed

**Implants**

- 3 yrs
- HCP required
- Light bleed

**Injectables**

- In 2 or 3 monthly inj
- Unpredictable bleeds
- Frequently amenorrhea delayed return to fertility

**COC**

- Regular bleed
- Non contraceptive benefits

**Patch**

**Ring**

**POP**

- Can be used when E is C/I
  - Unpredictable bleeds
  - Scanty menses
  - Good for lactating mothers

**Check MEC**
Selection for reversible contraceptive

- Access age, history
- Basic examination (general, breast, pelvic)
- Review medical history
- Current medications
- Duration of contraception devices

Categorize according to patient need and MEC

1. Adolescents
2. Medical disorders
3. Postpartum/post aborted
4. Perimenopausal
5. Special categories

C/I: contraindicated; COCs: combined oral contraceptive; DMPA: depo-medroxyprogesterone acetate; EC: emergency contraception; HCP: health care provider; IUD: Intrauterine device; LNG-IUS: levonorgestrel intrauterine system; MEC: medical eligibility criteria; POP: progestin-only pills; SC: subcutaneous; STI: sexually transmitted infections.
ECTOPIC PREGNANCY

Preface

Ectopic pregnancy is a high-risk condition wherein a fertilized ovum gets implanted outside the uterine cavity. This condition poses a significant threat to women of reproductive age and is a leading cause of maternal death during the first trimester. It is reported to affect around 1% to 2% of all pregnancies. Risk factors for ectopic pregnancy include surgery or infection that causes tubal damage, as well as maternal smoking and in vitro fertilisation. However, the majority of women with an ectopic pregnancy have no identifiable risk factor. Advances in diagnosis and treatment of ectopic pregnancy have reduced the mortality rates by 50%.

First-trimester bleeding and abdominal pain may be indicative of common symptoms of an unruptured ectopic pregnancy. It is essential to consider ectopic pregnancy when a pregnant woman presents with these symptoms. The details involving clinical history on pregnancy dating, the onset and intensity of symptoms, and a review of risk factors can help in determining the best diagnostic course, as well as the speed of processing the workup. Noting the severity of symptoms is important; especially for those with more severe bleeding, and hemodynamic instability. Surgical treatment may be warranted in such cases. The following flowcharts may help in guiding the diagnostic and treatment approaches for patients with ectopic pregnancy.
**ECTOPIC PREGNANCY**

**PUL**

- **Repeat β hCG Measurement Every 48 hrs**
  - β hCG levels decrease
    - Failed pregnancy (intrauterine or ectopic)
      - Weekly β hCG measurement until negative
    - Intrauterine pregnancy
  - β hCG shows normal rise
  - β hCG levels plateaus or shows suboptimal rise
    - TVS when discriminatory level is reached
    - TVS

**Failed pregnancy** (intrauterine or ectopic)

**Intrauterine pregnancy**

**Adnexal mass**

**Negative**

**Medical or surgical treatment**

**Failed pregnancy** (intrauterine or ectopic)

**Medical or surgical treatment**

**Incidence 11/1,000**

**Classical triad**
- Amenorrhea
- Pain
- Bleeding

**Ectopic pregnancy**

**Risk factors**
- History of PID
- Tubal surgery /ligation
- Previous ectopic pregnancy
- Infertility
- ART
- Smoking
- Maternal age >40
- Pregnancy with IUCD

- Ampullary
- Isthmic
- Cornual
- Interstitial
- Scar
- Ovarian
- Abdominal
- Cervical
Ectopic pregnancy

Initial Assessment
- Vital signs
- UPT/β hCG (whenever possible)

Haemodynamically unstable

Haemodynamically stable
- β hCG
- TVS (tool of choice)
- TAS (if TVS not available)

Presumptive ruptured ectopic pregnancy/hemorrhage

Immediate surgical treatment

Empty uterine cavity
- In homogenous/ non-cystic adnexal mass
- No specific endometrial sign
- Free fluid in POD is not diagnostic

Management

Expectant

Medical

Surgical

Indications
- Ready to come for follow up
- No significant pain
- β hCG <1500 mIU

Repeat β hCG after 48 hrs

Falling level
- Follow up weekly with β hCG till levels <5 mIU

Increasing levels
- Manage as per medical management/surgical
Indications
- No significant pain
- Adnexal mass <35 mm
- β hCG: 1500 to 5000 mIU
- No visible heart beat
- No intrauterine pregnancy

Methotrexate (drug of choice)

Multiple doses
- 1, 3, 5 and 7th day (50 mg/m²)
- Inj Leucovorine 0.1 mg/kg on 2, 4, 6, & 8th day

Medical

Single dose preferred
50 mg/m²
Repeat β hCG on Day 4 & Day 7

D1:
- Haemogram (CBC)
- LFT, RFT, Rh type; blood group

If decrease >15%
F/U with weekly β hCG till <5 mIU

If decrease is <15%
2nd dose of Inj methotrexate Weekly β hCG till negative

Decrease if >15%
Weekly β hCG till negative

If decrease is <15%

<table>
<thead>
<tr>
<th>Treatment day</th>
<th>Laboratory evaluation</th>
<th>Intervention</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-treatment</td>
<td>hCG, CBC with differential, liver function tests, Creatinine, blood type, and antibody screen</td>
<td>Rule out spontaneous abortion RhoGAM if Rh negative</td>
</tr>
<tr>
<td>1</td>
<td>hCG</td>
<td>MTX 1.0 mg/kg IM</td>
</tr>
<tr>
<td>2</td>
<td></td>
<td>LEU 0.1 mg/kg IM</td>
</tr>
<tr>
<td>3</td>
<td>hCG</td>
<td>MTX 1.0 mg/kg IM if &lt;15% decline day 1 – day 3 if &gt;15%, stop treatment and start surveillance</td>
</tr>
<tr>
<td>4</td>
<td></td>
<td>LEU 0.1 mg/kg IM</td>
</tr>
<tr>
<td>5</td>
<td>hCG</td>
<td>MTX 1.0 mg/kg IM if &lt;15% decline day 3 – day 5 if &gt;15%, stop treatment and start surveillance</td>
</tr>
<tr>
<td>6</td>
<td></td>
<td>LEU 0.1 mg/kg IM</td>
</tr>
<tr>
<td>7</td>
<td>hCG</td>
<td>MTX 1.0 mg/kg IM if &lt;15% decline day 5 – day 7 if &gt;15%, stop treatment and start surveillance</td>
</tr>
<tr>
<td>8</td>
<td></td>
<td>LEU 0.1 mg/kg IM</td>
</tr>
</tbody>
</table>

Note: suverilance every 7 days (until hCG < 5 mIU/mL), screening laboratory studies should be repeated every week after the last dose of MTX, CBC= complete blood count, MTX= methotrexate, IM=intramuscularly, LEU= leucovorin.
Surgical

Laparoscopy
Laparotomy
(if laparoscopy not possible)

Salpingectomy
Indications
- Healthy contralateral tube
- No other fertility reducing factor
- Family complete (Contralateral tubal sterilization may be offered)

Salpingotomy
Indications
- Contralateral tube damage
- Other fertility reducing factors
- Desires fertility

F/U with β hCG after 7 days and weekly thereafter till <5 mIU

If levels plateau/increasing (persistent trophoblast) then manage medically

Salpingotomy
With tubal repair (in expert hands)

Cervical pregnancy

- Medical management is the choice with systemic methotrexate
- Surgical management only if life threatening bleeding

Scar pregnancy

- Medical management is the choice with systemic methotrexate
- Surgical management only if life threatening bleeding

Acute uterine bleeding (AUB) which is unrelated to pregnancy has been described as “bleeding that is sufficient in volume as to, in the opinion of the treating clinician, require urgent or emergent intervention”. Many women of reproductive age experience acute bleeding when not pregnant, but this aspect has not received much attention. Also, uterine hemorrhage occurs secondary to pregnancy.

AUB is a relatively common clinical condition in women and can be source of distress and a challenge for clinicians; and many of these women are managed with inpatient surgical procedures. Medical treatment with single or combined gonadal steroidal drugs given parenterally or orally show promise, but further researcher is need to better define the appropriate drugs, dose, and administrative scheduling.

In case of women with AUB medical management should be the first-choice. Surgical approaches should be considered unless bleeding is suspected to related to retained products of conception or from intrauterine lesions such as aborting submucous leiomyomas.
ACUTE UTERINE BLEEDING

### AUB

- History
- Rule out pregnancy
- Examination
- Cervical cytology if appropriate
- CBC, TSH, USG (TVS±SIS)

#### Increased risk of hyperplasia/Malignancy (AUB-M, AUB-COEIN)

- Endometrial sampling

  - Specimen adequate
  - Specimen inadequate

    - Medical management

#### Suspicion of intracavity pathology (polyp/SM fibroid/malignancy (AUB-P, AUB-M))

- Hysteroscopy & proceed

  - Family not complete
  - Family complete

    - UAE
    - Myomectomy

#### Suggestive of structural problem (Myoma/Adenomyosis)

- Fibroid (AUB-L)

  - Family not complete
  - Family complete

    - UAE/HIFU
    - Medical management, COCP, Ulipristal, GnRHa, Low dose Mifepristone

#### No structural problem; possibly hormonal (AUB-COEIN)

- Adenomyosis (AUB-A)

  - Prefers to retain uterus
  - UAE/HIFU

- Offer hysterectomy if family complete & over 40 years

#### Wants fertility:

- Trenaxamic acid
- Progesterones esp Dienogest
- GnRHα short term
- Adenomyomectomy

#### Family complete; young or wants to preserve uterus

- Dienogest/LNG IUS/GnRHa
- Adenomyomectomy

#### Does not want to preserve uterus & > 40 years

- Offer hysterectomy if family complete & over 40 years
No structural problem; possibly hormonal (AUB-COEIN)

Medical management
- Tranexamic acid
- Mefenamic acid
- COC pills
- LNG IUS
- Ormeloxfene
- Cyclical progesterone (21/28 days)
- Inj DMPA

Succeeds
- Continue medical management

Fails
- Offer endometria ablative procedures if family complete
- Offer hysterectomy if family complete and over 40 years

1. History
   Age, H/o amennorhoea, history suggestive of bleeding disorder, hormone intake (Progesterone/COCP/Danazol/Tamoxifen), h/o drug intake (antithrombotics etc), risk factors eg DM, Hypertension, Obesity, Thyroid disorders.

2. When to investigate?
   AUB persisting for 3 months
   Any AUB causing anaemia
   Any postmenopausal bleeding

3. Other specific tests
   SIS only if doubtful intracavity pathology
   Tests for coagulation (suggestive history, puberty menorrhagia)
   MRI for pre-op evaluation of fibroids if indicated

4. Pre-operative investigations
   Increased risk of hyperplasia/malignancy
   Women 40 years, Intermenstrual bleeding, DM, Obesity, Hypertension, Prolonged unopposed exposure to estrogen

5. Postmenopausal bleeding
   Any postmenopausal bleeding needs an ultrasound assessment on Endometrial thickness (ET) preferably by TVS. Hysteroscopy with curettage is indicated if ET 4mm.

6. Endometrial carcinoma
   Treatment is total hysterectomy with bilateral salpingo-oophorectomy with bilateral pelvic lymphadenectomy

7. Pre-treatment of Myoma prior to surgery
   Only indicated for hysteroscopic myomectomy for submucus fibroids 4cm or severe anaemia while waiting for surgery
   GnRHa or Ulipristal acetate used
   Reduces fibroid volume
   May obscure tissue planes

8. Management of acute bleeding
   Tranexamic acid (may need parental) & high dose hormones (Progesterones/COCP;Estrogen)

9. Coagulopathy
   May need replacement of coagulation factors
   Treatment with hormones & tranexamic acid (no NSAID)

CBC: complete blood count; COCP: Combined oral contraceptive pills; DMPA: depot medroxyprogesterone acetate; GnRHa: Gonadotropin releasing hormone agonist; HiFU: High-Intensity Focused Ultrasound; LNG_IUS: Levonorgestrel intra-uterine system; TSH: Thyroid-stimulating hormone; UAE: Uterine artery embolization; USG: ultrasonography.
The group that brought you the legendary progesterone

IF IT'S ORALLY EFFECTIVE IT'S

duphaston®
Dydrogesterone Tablets IP 10mg

HAS SUPPLEMENTED IT'S RANGE

In accordance with THE GLOBAL FORMULATION™

RX

CystoFert Chewables
Myo-Inositol 150mg, Inositol 77mg (as D-Chiro-Inositol), Folic Acid 1mg Tablets

THE PCOS Supplement

And has the oral 17 β-estradiol identical to endogenous human estrogen†

RX

Estrabet
Estadiol (as Estradiol Benzoate Tablets) 1mg/0.5mg

Along with another Pro in maternal care

RX

Pro
Hydroxyprogesterone Injection IP 200 mg/400 mg

The approved progesterone delivering full-term

Further Information available on request from: Abbott India Limited, 3rd Corporate Park, San-Thombay Road, Chennai, Mumbai 400077, India, www.abbott.co.in
* Registered trademark of the Abbott Group of Companies, Copyright (C) 2011 Abbott, All rights reserved.
THANK YOU FOR YOUR TRUST THAT MADE US

The World’s No.1

Progestogen*

DUHASTRON®

Dydrogesterone Tablets IP 10mg


Abbreviations: Premarin® = conjugated equine estrogens; Estrace® = ethinyl estradiol; Progestin® = mestranol; Micronor® = levonorgestrel; Norplant® = medroxyprogesterone acetate; Ortho-Novum® = norethindrone acetate; PMS = placebo; Nolvadex® = tamoxifen; HRT = hormone replacement therapy; PHE = percutaneous estrogens; TDD = transdermal delivery; FEM = female estrogen; FSH = follicle stimulating hormone; LH = luteinizing hormone; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobulin E; FSH = follicle stimulating hormone; LH = luteinizing hormone; IgE = immunoglobul

For the use of a Registered Medical Practitioner or a Hospital or a Laboratory only.